R&D History
2019 University of Dundee partners with Bukwang Pharmaceutical Company to tackle new drug treatment for Parkinson’s disease
2019 Bukwang Announced commencement of Phase 2 Clinical Study of JM-010 in major European countries
2018 Bukwang Announces completion of dosing of MLR-1023’s phase 2b study.
2018 Bukwang initiates phase 3 study with lurasidone HCl for patients with Schizophrenia
2018 Bukwang Pharmaceutical Co., Ltd.(“Bukwang”) registered patents on a therapeutic candidate for Levodopa-induced dyskinesia
in Parkinson’s disease. - International application and registration of patents on therapeutic use and composition, formulations and
metabolites for Levodopa-induced dyskinesia in Parkinson’s disease.
2017 MLR-1023, a novel type 2 diabetic drug candidate, global Phase 2b subject enrollment has initiated
2017 JM-010, a treatment of dyskinesia in PD patients, received orphan drug designation from Korea MFDS
2017 Signed an Korea exclusive license agreement of lurasidone HCl, new drug for schizophrenia, with Sumitomo Dainippon
Pharma
2016 Bukwang has entered a distribution deal with Kalbe International Pte. Ltd. to export "Dexid Tab" to six countires,
including Philippines and Vietnam.
2016 Anticancer agent Apatinib Mesylate designated orphan drug from Korea MFDS
2015 Phase 2a study of anti-diabetic agent MLR-1023 and Phase 2 study of LID (levodopa-induced dyskinesia) candidate
JM-010 each completed
2014 Acquired 100% shares of Danish biotech Contera Pharma
2014 Signed license agreement on JM-010, a candidate for movement disorder in Parkinson’s disease
2013 Acquired approval in Korea for Dexid Tab 480mg (R-thioctic acid tromethamine salt), R-form thioctic acid
developed independently by Bukwang
2013 Signed license agreement on MLR-1023, an anti-diabetic candidate
2009 Signed license agreement on YN968D1 (apatinib mesylate), an anti-cancer candidate and
VEGFR inhibitor
2009 Acquired approval in Korea for Lonasen Tab. 2mg and 4mg, new drugs for schizophrenia
developed by Sumitomo Dainippon Pharma in Japan
2007 Acquired approval in Korea for Nadixa Cream (nadifloxacin), new anti-acne drug developed
by Ferrer in Spain
2006 Acquired approval in Korea for Levovir Cap. 30mg (clevudine), the 11th new drug
in Korea and a new drug developed by Bukwang
2004 Acquired approval in Korea for Somazina Tab. 500mg (citicoline), a new drug for
stroke developed by Ferrer in Spain
2002 Acquired approval in Korea for Thioctacid HR Tab. 600mg and 200mg,
new drug for diabetic neuropathy, developed by Meda in Sweden
2001 Acquired approval in Korea for Asima Tab. (doxofylline), a new drug for COPD and asthma,
developed by Eurodrug in Ireland
2000 Acquired approval in Korea for Ixel Cap. 50mg and 25mg (milnacipran HCl),
a new anti-depressant developed by Pierre Fabre in France
1998 Acquired approval in Korea for Thioctacid Tab. 200mg (thioctic acid), a new drug for diabetic neuropathy
1998 Acquired approval in Korea for Legalon Cap. 140 (Carduus marianus extract powder), a new drug for liver diseases
1995 Acquired approval in Korea for Navelbine Inj. (vinorelbine tartrate), a new anti-cancer drug
for non-small cell lung cancer and progressive breast cancer
1990 Acquired approval in Korea for Bukwang Azeptin Tab. (azelastine HCl), a new drug for allergic rhinitis
1990 Acquired approval in Korea for Orfiril SR Tab. 300mg (sodium valproate), a new drug for epilepsy and mania
1986 Acquired approval in Korea for Bukwang Kerlone Tab. (betaxolol HCl), a new beta-blocker
for high blood pressure developed by Sanofi-Aventis in France
1978 Acquired approval in Korea for Primalan Tab. (mequitazine), a new drug for rash and allergic rhinitis
1974 Acquired approval in Korea for Synthyroid Tab. 0.1mg (levothyroxine sodium hydrate), a new drug
for hypothyroidism